Should you build or buy Electronic Trial Master File (eTMF)?

Electronic Trial Master File software is the regulated document repository that proves a clinical trial was run to standard: protocols, consent forms, monitoring visit reports and correspondence, organized to the industry's reference taxonomy and ready for an inspector's direct access. Buyers are pharmaceutical and biotech sponsors and the CROs running trials on their behalf.

Only in a narrow case. A capable academic unit can configure SharePoint or a content platform into a TMF with document controls, and Nottingham CTU has, but the regulated sponsor or CRO still owns validation, completeness metrics, exchange, inspector access and retention, and custom-build estimates run from $80k to $650k before that work. Buy a purpose-built eTMF, use AI-assisted classification as a qualified assist rather than the record, and negotiate the Veeva bundle on scope rather than assuming a list price.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
A validated custom platform runs well into six figures before the staff needed to keep it validated.
Vendor pricing is negotiated and quote-based, but bundles validation evidence the sponsor would otherwise build alone.
A lean team can run a document platform it already licenses for a single low-risk study.
Time to value
Months of validation work before the system can hold a single real document.
A purpose-built eTMF arrives with the reference taxonomy and inspector-access model already built in.
A CRO-shared governance split ships faster than either party building an eTMF from zero.
Differentiation captured
None: every sponsor files to the same reference model and the same inspection expectations.
The vendor owns the certified document platform; the sponsor's edge is trial design, not filing.
No blend changes the underlying obligation, which is identical for every sponsor and every CRO.
AI feasibility today
AI can't replace the validation and completeness-tracking work a configured platform still needs.
Vendors add AI-assisted document classification on top of an already-validated repository as a time-saver.
Treat AI classification as a qualified assist on either path, never as the record itself.
Who it fits
A well-resourced academic clinical trials unit running its own studies with dedicated document-control staff.
Any sponsor or CRO managing a study that will face inspection, especially with several trials.
A lean sponsor that lets a CRO's own eTMF hold some studies and keeps others in-house.

When building makes sense

A capable clinical trials unit can build a working eTMF on a document platform it already owns. Nottingham's Clinical Trials Unit published exactly this on GitHub: setup instructions for running an eTMF in Microsoft SharePoint, plus a Power Automate approval flow, with a plain disclaimer that anyone using it does so at their own risk. That disclaimer is the honest summary of the build case. The document management and taxonomy pieces are genuinely reproducible, and an academic unit with in-house SharePoint expertise and no commercial inspection pressure can run it. What a build does not remove is the sponsor's own responsibility for completeness tracking, document exchange with CROs and partners, and inspector access during a live audit. Those are operational commitments that follow the sponsor forever, not a one-time configuration project, which is why this stays a narrow case rather than a mainstream one.

When buying makes sense

The more representative story is OM Pharma's, and it points the other way. The company ran its trial master file on SharePoint, a general document repository that wasn't purpose-built for clinical trials, and it created real barriers to inspection readiness for a lean team running five studies with two CROs. Moving to Veeva eTMF, along with a hybrid governance model that let some CROs work in the sponsor's own system, improved TMF completeness by more than 40% within three months. That is the buy case in one data point: a small team got measurably better outcomes from a purpose-built system than from a general tool doing the job by improvisation. Buy a dedicated eTMF once you are managing more than a handful of trials or working with CROs who need a shared system of record, and negotiate the vendor's price on your actual document volume rather than a list rate.

The desk read

Build-versus-buy analysis for Electronic Trial Master File (eTMF) is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.

Representative vendors Florence eTMFMontrium Connect eTMF + 4 more, listed in the full index

Frequently asked

Has anyone actually run a real trial's TMF on SharePoint instead of a commercial system?

Nottingham's Clinical Trials Unit built and published a working SharePoint eTMF setup, including an approval workflow, and explicitly warns that use is at your own risk. OM Pharma also started on SharePoint before moving away from it, describing it as a barrier to inspection readiness rather than a solution.

What actually improved for OM Pharma after switching platforms?

OM Pharma's clinical operations team improved trial master file completeness by more than 40% within three months of adopting Veeva eTMF and a hybrid governance model with its CROs. The improvement came from completeness dashboards and expected-document lists that flagged gaps the SharePoint setup never surfaced.

Does buying an eTMF transfer the sponsor's regulatory responsibility to the vendor?

No. A vendor's certification claims describe the software, not a specific sponsor's implementation. The sponsor or CRO still owns validating the system for its intended use, tracking completeness and making documents available to inspectors on demand.

Is a hybrid governance model, where the sponsor and CRO use different systems, a real option?

Yes, and OM Pharma runs one: for some studies its CRO works inside the sponsor's own Veeva eTMF, and for others each party keeps a separate system and the CRO transfers documents at study end. The right model depends on study size, CRO capability and available budget.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.

More in Clinical Trials & Research Operations

Build or buy Clinical Trial Management (CTMS)? Build or buy Clinical Trial Payments & Site Budget Management? Build or buy ePRO / eCOA (Electronic Clinical Outcome Assessment)? Build or buy Randomization & Trial Supply Management (RTSM/IRT)? Build or buy Electronic Data Capture (EDC)? Build or buy Cell & Gene Therapy Orchestration?